Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Clinical Trials Related to Trastuzumab
Related studies linked through entity extraction aliases.
TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery
- Status
- UNKNOWN
- Phase
- PHASE2
Study Comparing EC-T Verses PCb in the Adjuvant Chemotherapy of Non-triple Negative Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
ACHP-THP vs EC-THP as Neoadjuvant Therapy for HER2-positive EBC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Trastuzumab to Patients With Advanced Gastric Cancer With HER2 Positive Expression in CTC
- Status
- TERMINATED
- Phase
- PHASE2
Adjuvant Dual Anti-HER2 Therapy in Patients With Small, Node-negative, HER2-positive Breast Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin America
- Status
- COMPLETED
- Phase
- N/A
Pyrotinib Maleate Tablets Combined With Albumin Paclitaxel and Trastuzumab for Her2-positive Breast Cancer
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
Oxaliplatin and Liposomal Irinotecan (Plus Trastuzumab for HER2-positive Disease) in Advanced Esophageal and Gastric Adenocarcinoma
- Status
- RECRUITING
- Phase
- PHASE2
Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast Cancer
- Status
- SUSPENDED
- Phase
- PHASE1
Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
A Window-of-opportunity Study of Pelareorep in Early Breast Cancer
- Status
- TERMINATED
- Phase
- EARLY_PHASE1
Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Pyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer
- Status
- COMPLETED
- Phase
- PHASE2/PHASE3
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
- Status
- TERMINATED
- Phase
- PHASE2
Pharmacokinetic, Safety and Immunogenicity Study of CMAB809 and Herceptin in Healthy Volunteers
- Status
- COMPLETED
- Phase
- PHASE1
KN035 in Combination With Trastuzumab and Docetaxel in HER2-positive Breast Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
Pegylated Liposomal Doxorubicin Plus Albumin-Bound Paclitaxel and Trastuzumab in HER-2 Positive Breast Cancer
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2